



NEWS RELEASE

CareDx Completes Acquisition of ImmuMetrix

Brisbane, CA, June 11, 2014 -- CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it has completed its previously announced acquisition of ImmuMetrix, Inc. ImmuMetrix is a privately held Palo Alto, California based development-stage transplant diagnostics company founded by Stephen Quake, D.Phil., with R&D programs and intellectual property in cell-free DNA.

"We look forward to a quick integration of the talented team at ImmuMetrix into CareDx," said Matthew J. Meyer, Chief Business Officer of CareDx. "We believe that the cell-free DNA platform in Dr. Quake's lab, combined with our own cell-free DNA research efforts and existing commercialized AlloMap test for heart transplant recipients, creates the potential to develop better organ transplant surveillance options for health care providers and their patients."

"Bringing our two companies together strengthens the technologies available for organ transplant surveillance which will lead to potential, additional non-invasive options for transplant monitoring," said Bruce Hironaka, President and Director at ImmuMetrix, Inc.

About AlloMap®

AlloMap MolecularTesting is a non-invasive gene expression test used to aid in the identification of heart transplant recipients who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive gene-expression test and surveillance solutions for transplant recipients. The company commercializes AlloMap, which aids clinicians in identifying heart transplant recipients with stable graft function.

For more information, please visit: www.CareDxInc.com.

Contacts

Company

Bradley P. Sherrill
Senior Director, Marketing
Tel: 415-287-2397
bsherrill@CareDxInc.com